Neuberger Berman Amends Standard BioTools Stake, Signals Active Interest

TL;DR

**Neuberger Berman just upgraded their filing on Standard BioTools, signaling they're getting more involved!**

AI Summary

Neuberger Berman Group LLC, along with several affiliated entities and individuals including Amit Solomon and Benjamin Nahum, filed an amended Schedule 13D/A on January 12, 2024, indicating a change in their beneficial ownership of STANDARD BIOTOOLS INC. common stock. This amendment updates their previous filing, which was initially a Schedule 13G, and is now being filed as a 13D due to a change in reporting requirements. This matters to investors because it signals a more active interest or potential influence from Neuberger Berman in STANDARD BIOTOOLS, which could lead to strategic changes or increased scrutiny of the company's operations.

Why It Matters

This filing indicates Neuberger Berman is taking a more active role in STANDARD BIOTOOLS, potentially influencing future company decisions and strategy, which could impact stock performance.

Risk Assessment

Risk Level: medium — A change from a passive 13G to an active 13D filing suggests potential for increased shareholder activism or strategic shifts, which can introduce both opportunities and risks.

Analyst Insight

An investor should monitor future filings from Neuberger Berman and STANDARD BIOTOOLS for any indications of strategic changes or shareholder engagement, as this shift from a passive 13G to an active 13D suggests a more hands-on approach.

Key Numbers

• 34385P108 — CUSIP Number (identifies the Common stock of STANDARD BIOTOOLS INC.)
• January 5, 2024 — Date of Event (the date triggering the requirement for this filing.)
• 005-86635 — SEC File Number (identifies STANDARD BIOTOOLS INC.'s registration with the SEC.)

Key Players & Entities

• Neuberger Berman Group LLC (company) — the filing person and a significant investor in STANDARD BIOTOOLS INC.
• STANDARD BIOTOOLS INC. (company) — the subject company whose securities are being reported.
• Amit Solomon (person) — a group member associated with Neuberger Berman's filing.
• Benjamin Nahum (person) — a group member associated with Neuberger Berman's filing.
• William Braverman ESQ (person) — the person authorized to receive notices for Neuberger Berman Group LLC.

Forward-Looking Statements

• Neuberger Berman Group LLC will seek to engage with STANDARD BIOTOOLS INC. management regarding strategic direction. (Neuberger Berman Group LLC) — medium confidence, target: Q2 2024
• STANDARD BIOTOOLS INC. stock price may experience increased volatility due to perceived activist interest. (STANDARD BIOTOOLS INC.) — medium confidence, target: Q1 2024

FAQ

Filing Documents

• formsc13da-01122024_070144.htm (SC 13D/A) — 175KB
• ex1-01122024_070144.htm (EX-1) — 85KB
• 0001415889-24-001017.txt ( ) — 262KB

Security and Issuer

Item 1. Security and Issuer

of the Schedule 13D is hereby amended and supplemented as follows

Item 1 of the Schedule 13D is hereby amended and supplemented as follows: This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the information set forth in the Schedule 13D filed by the Reporting Persons with the U.S. Securities and Exchange Commission (the "SEC") on November 18, 2021 ("Amendment No.1" and, together with the Initial Schedule 13D, the "Schedule 13D"), relating to the class of equity securities to which this statement on Schedule 13D relates is the common stock (the "Securities") of Standard Biotools Inc., a California corporation (the "Issuer"), having its principal place of business at 2 Tower Place, Suite 2000 South San Francisco, CA, 94080. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D.

Identity and Background

Item 2. Identity and Background (c) Item 2(c) of the Schedule 13D is hereby amended to restate the information required by instruction C to Schedule 13D as follows: The information required by instruction C to Schedule 13D with respect to the directors and executive officers of the Reporting Persons is set forth below. Neuberger Berman Group LLC Directors Joseph Amato Sharon Bowen Robert D'Alelio Michele Docharty Steven Kandarian George Walker Richard Worley Executive Officers George Walker, Chief Executive Officer Joseph Amato, President Andrew Komaroff, Executive Vice President and Chief Operating Officer Heather Zuckerman, Executive Vice President, Chief of Staff and Secretary William Arnold, Executive Vice President and Chief Financial Officer Michael Chinni, Treasurer Leo Anthony Viola, Controller Neuberger Berman Investment Advisers LLC Directors Joseph Amato Kenneth deRegt Douglas Kramer Bradley Tank Stephen Wright Executive Officers Joseph Amato, President - Equities and Chief Investment Officer â Equities Bradley Tank, President - Fixed Income and Chief Investment Officer â Fixed Income Kenneth deRegt, Chief Operating Officer - Fixed Income and Managing Director Patrick Deaton - Chief Operating Officer - Alternatives and Managing Director Paul Lanks - Chief Operating Officer - Private Wealth Douglas Kramer, Head of Institutional Equity and Multi-Asset and Managing Director Irina Babushkina, Chief Administrative Officer - Global Research and Senior Vice President Beryl Lou, Head of Investment Engineering and Vice President Brian Kerrane, Head of Mutual Fund Administration and Managing Director Brad Cetron, Chief Compliance Officer, Head of Compliance and Managing Director Michael Chinni, Treasurer and Senior Vice President Leo Anthony Viola, Controller and Managing Director Savonne Ferguson, Chief Compliance Officer - Mutual Funds and Senior Vice President Neuberger Berman Canada ULC Directors Joseph

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. (a)

(a) - (c) and (e) of the Schedule 13D is hereby amended and supplemented as follows

Item 5 (a) - (c) and (e) of the Schedule 13D is hereby amended and supplemented as follows: See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of and percentages of the shares of Common Stock beneficially owned by each Reporting Person. The percentages set forth in this Schedule 13D are based upon the Reporting Person's calculation of 289,464,031 shares of Common Stock outstanding, based upon (i) 80,030,193 shares of Common Stock outstanding as of November 29, 2023, as reported in the Issuer's prospectus filed pursuant to Rule 424(b)(3) with the Securities and Exchange Commission on December 22, 2023 ("the Prospectus"), plus (ii) 209,433,838 shares of Common Stock used as merger consideration in connection with the Issuer's transaction with SomaLogic, Inc., a Delaware corporation ("Somalogic") (representing a 1.11 fixed exchange ratio over 188,679,133 shares of SomaLogic common stock outstanding as of November 29, 2023, as reported in the Prospectus). As a result of the consummation of the transaction between the Issuer and SomaLogic (as reported in the Form 8-K filed by the Issuer on January 5, 2024), the Reporting Persons' beneficial ownership of Common Stock has been reduced below 5% of the outstanding shares of Common Stock. (b) See Rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. (c) Information concerning transaction in the shares of Common Stock reported herein effected during the past sixty (60) days is set forth in Schedule 1, which is attached hereto and is incorporated herein by reference. All of the transactions in the shares of Common Stock listed therein were effected in the open market through various brokerage entities. (d) The Reporting Persons effected the following transactions in the Securities

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits EX-1.1 The Reporting Persons effected the following transactions in the Securities during the past sixty days. Such transactions were effected in the open market.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 12, 2024 Neuberger Berman Group LLC By: /s/ Joseph Amato Name: Joseph Amato Title: President Date: January 12, 2024 Neuberger Berman Investment Advisers LLC By: /s/ Joseph Amato Name: Joseph Amato Title: President - Equities Date: January 12, 2024 Neuberger Berman Investment Advisers Holdings LLC By: /s/ Andrew Komaroff Name: Andrew Komaroff Title: President Date: January 12, 2024 Neuberger Berman Canada Holdings LLC By: /s/ Ray Carroll Name: Ray Carroll Title: Chief Executive Officer Date: January 12, 2024 NB Acquisitionco ULC By: /s/ Ray Carroll Name: Ray Carroll Title: Chief Executive Officer Date: January 12, 2024 Neuberger Berman Canada ULC By: /s/ Ray Carroll Name: Ray Carroll Title: Chief Executive Officer Date: January 12, 2024 By: /s/ Benjamin Nahum Name: Benjamin Nahum Date: January 12, 2024 By: /s/ Amit Solomon Name: Amit Solomon Date: January 12, 2024 By: /s/ Rand Gesing Name: Rand Gesing Date: January 12, 2024 By: /s/ Pong Chan Name: Pong Chan Exhibit Index Exhibit No. Description EX-1.1 The Reporting Persons effected the following transactions in the Securities during the past sixty days. Such transactions were effected in the open market.

View Full Filing

View this SC 13D/A filing on SEC EDGAR